Mark has 30 years of clinical and regulatory pharmaceutical industry experience and was the Founder and CEO of Impact Pharmaceutical Services for 12 years before it was acquired by Syner-G in early 2022. As a member of the Syner-G Executive Leadership Team, Mark leads the regulatory strategy and submissions group and plays an active role in consulting on regulatory and clinical drug development strategies for Syner-G clients and interacting with the US FDA on their behalf. His biomedical research experience covers a broad range of therapeutic areas and includes work on both drugs and biologics at all phases of development. Mark’s team is also responsible for making global electronic submissions on behalf Syner-G clients.